comparemela.com

Latest Breaking News On - Targeted radionuclide therapy - Page 3 : comparemela.com

ITM, Helmholtz Munich and University Hospital Münster

Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company,.

Reinhard zeidlerBen orzelekDeutsches forschungszentrumWalter stummerThomas bauerVerena cosciaSteffen schusterJulia hofmann svenjaUmwelt gmbDepartment of neurosurgeryUniversity hospitalNuclear medicineCorporate communicationsHelmholtz associationTargeted radionuclide therapyHelmholtz munich

ITM Isotope Technologies Munich SE: ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

Garching/Munich, Munich and Münster, Germany, March 13, 2023 - ITM Isotope Technologies Munich SEand the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster today announced

Dennis riedlReinhard zeidlerBen orzelekWalter stummerThomas bauerVerena cosciaSteffen schusterJulia hofmann svenjaDepartment of neurosurgeryUniversity hospitalNuclear medicineCorporate communicationsHelmholtz associationTechnologies munichTargeted radionuclide therapyHelmholtz munich

ITM Isotope Technologies Munich SE: ITM Signs Clinical Supply Agreement with Y-mAbs for n c a Lutetium-177

ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs' Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive solid

Valeria fisherBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaCorporate communicationsY mabs therapeutics incTrophic communicationsDeutsche bank freiburgPharma solutions gmbY mab targeted radionuclide therapyTechnologies munichY mabs therapeuticsTargeted radionuclide therapyRadionuclide therapyBank freiburg

Investegate |ITM Isotope Technologies Munic Announcements | ITM Isotope Technologies Munic: ITM Signs Clinical Supply Agreement with Y-mAbs for n c a Lutetium-177

Investegate announcements from ITM Isotope Technologies Munic, ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177

Valeria fisherBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaUdoj vetterCorporate communicationsY mabs therapeutics incDistrict courtTrophic communicationsDeutsche bank freiburgPharma solutions gmbClinical supply agreementY mab targeted radionuclide therapyTechnologies munichY mabs therapeutics

ITM Signs Clinical Supply Agreement with Y-mAbs for n c a Lutetium-177

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Valeria fisherBen orzelekSteffen schusterJulia hofmann susanne karlssonLu endolucinbetaUdoj vetterCorporate communicationsY mabs therapeutics incDistrict courtTrophic communicationsDeutsche bank freiburgPharma solutions gmbY mab targeted radionuclide therapyTechnologies munichY mabs therapeuticsTargeted radionuclide therapy

vimarsana © 2020. All Rights Reserved.